How can DEGARELIX FERRING help with disease-related symptoms?
What are the relative risk reductions of these symptoms when treating with DEGARELIX FERRING vs LHRH agonists?
These common symptoms can have a negative effect on patients’ quality of life,2,3 potentially impacting the NHS burden:
Urinary-tract problems
Urinary-associated problems, e.g. obstructive uropathy leading to persistent infections and LUTS
Bone and back pain
As a result of arthralgia, or eventually bone metastases which can lead to fractures and spinal cord compression
DEGARELIX FERRING is significantly more effective in controlling disease-related symptoms vs. LHRH agonists1
relative risk reduction in joint-related symptoms1†
relative risk reduction in LUTS1‡
relative risk reduction in musculoskeletal events1§
† Absolute values for joint-related signs and symptoms are not reported in the paper.
‡ Crude incidence of a urinary tract event was 12% vs. 18% for DEGARELIX FERRING and LHRH agonist respectively.
§ Crude incidence of a musculoskeletal event was 8% vs. 12% for DEGARELIX FERRING and LHRH agonist respectively
How can DEGARELIX FERRING’s MOA help improve control of disease-related symptoms?
Compared with LHRH agonists, DEGARELIX FERRING blocks GnRH receptors leading to a rapid, profound and sustained suppression of testosterone, FSH, LH and PSA5
Use the buttons below to choose
A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing a musculoskeletal event1
A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing renal or LUTS adverse event1
